Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

The quest for specific anti-inflammatory treatment

08.01.2009
Anti-inflammatory drugs affect the cells taking part in inflammatory processes, but also those that do not. This is why it is important to develop specific anti-inflammatory drugs which affect healthy cells. With this aim in mind, a team from the University of the Basque Country is working on analogues of the C1P molecule.

Today two types of anti-inflammatory pharmaceutical drugs are available: steroids and those known as NSAID (Non-steroidal anti-inflammatory drugs). This second type are the most used, have fewer side-effects but they have an effect over a wider spectrum, i.e. they are less specific. Thus, there are no specific anti-inflammatory drugs for each cell type.

The team led by Antonio Gómez-Muñoz, from the Department of Biochemistry and Molecular Biology at the Science and Technology Faculty of the University of the Basque Country (UPV/EHU), is investigating alternatives to current anti-inflammatory drugs, creating synthetic analogues of the C1P (ceramide-1-phosphate) molecule. This molecule was discovered in 1990 in a case of human leukaemia After synthesising it in the laboratory, it was observed that it was an important mytogenic agent (provoking cell growth and blocking the natural death of the cells). Moreover, it causes cell inflammation, i.e. when the cells detect the presence of this molecule, they secrete molecules that generate inflammation - prostaglandin and cytokine cells, for example.

But this process does not occur with all types of cells. Although apparently contradictory, in some cells this same molecule functions in an anti-inflammatory manner. With this in mind, the Basque research team, annulling the inflammatory capacity of the C1P molecule, was able to use it as an anti-inflammatory drug for certain cell types without affecting other cells.

Removing one of the capabilities

To this end, and in collaboration with a research team from the University of Barcelona, they developed synthetic molecules similar in structure to that of C1P. The team is being led by doctors Josefina Casas and Gemma Fabriás, from the Consejo Superior para la Investigación Científica (CSIC) and includes Doctor Antonio Delgado from the University of Barcelona. They are the pharmacists and organic chemists who provide the UPV/EHU team with the made-to-measure molecules.

50 analogues of C1P have been tested to date of which three have provided the desired results, i.e. an anti-inflammatory function without causing inflammation in other cells These analogues do not generate prostaglandin, as does C1P and, thereby, do not produce any inflammation.

The three analogues mentioned have been tested with smooth muscle cells, with macrophages and with cancerous lung cells. The best results were obtained with the second and third type of cell. These types have been chosen as having a strong response to pro-inflammatory molecules.

Inflammation and cancer

Inflammatory processes may have various causes, an infection, for example. Chronic inflammatory diseases also exist, such as ulcerous colitis or multiple sclerosis, where, due to a constant state of inflammation, the cells are destabilised, provoking neoplasic processes, i.e. they generate new tissue of a tumorous nature. And this constant inflammation has great influence on the cells. They are destabilised and may cause an uncontrolled growth of the cells, even blocking their programmed death.

There are very few teams today researching the anti-inflammatory abilities of the C1P molecule – one team in Virginia (USA), the pharmaceutical company Novartis (Austria) and specific research teams such as that of Antonio Gómez-Muñoz, the first to investigate them in 1995. At present, the research is being undertaken at the cell level and shortly they should begin investigating with tissues and organs.

Lucía Álvarez | alfa
Further information:
http://www.elhuyar.com
http://www.basqueresearch.com/berria_irakurri.asp?Berri_Kod=2012&hizk=I

More articles from Life Sciences:

nachricht Desirable defects
30.04.2015 | International School of Advanced Studies (SISSA)

nachricht Rare Dune Plants Thrive on Disturbance
30.04.2015 | Washington University in St. Louis

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: HOBOS, das Bienenforschungsprojekt auf der Expo

„Den Planeten ernähren, Energie für das Leben“: So lautet das Motto der diesjährigen Expo in Mailand. Wenn es um Ernährung geht, spielen Bienen eine wichtige Rolle. Deshalb ist auch HOBOS, das Bienenforschungsprojekt der Uni Würzburg auf der Weltausstellung vertreten.

Etwa 20 Millionen Besucher erwarten die Organisatoren der diesjährigen Weltausstellung Expo in Mailand. Technologie, Innovation, Kultur, Tradition und...

Im Focus: Erosion, Hangrutschungen und Monsun quer durch den Himalaya

Der Himalaya hat gerade wieder auf tragische Weise gezeigt, dass diese Region Zentralasiens zu den geodynamisch aktivsten der Welt gehört. Hangrutschungen gehören zu den wichtigsten Georisiken.

Neben Erdbeben sind Starkregenfälle die Hauptauslöser für solche katastrophalen Hangbewegungen. Ein Team von Wissenschaftlern aus Nepal, der Schweiz und...

Im Focus: Erosion, landslides and monsoon across the Himalaya

Scientists from Nepal, Switzerland and Germany was now able to show how erosion processes caused by the monsoon are mirrored in the sediment load of a river crossing the Himalaya.

In these days, it was again tragically demonstrated that the Himalayas are one of the most active geodynamic regions of the world. Landslides belong to the...

Im Focus: Weltpremiere des Güterwagendrehgestells „SustRail conventional“

Auf der Internationalen Fachmesse „transport logistic“ vom 5. bis 8. Mai 2015 in München stellt das Fachgebiet Schienenfahrzeuge der TU Berlin erstmalig sein Güterwagendrehgestell „SustRail conventional“ der Öffentlichkeit vor. Besuchen Sie in Halle B 4 den Stand 430.

Das TU-Fachgebiet Schienenfahrzeuge hat gemeinsam mit 30 weiteren Partnern im Juni 2011 das von der Europäischen Kommission geförderte europäische...

Im Focus: Through the galaxy by taxi - The Dream Chaser Space Utility Vehicle

A world-class prime systems integrator and electronic systems provider known for its rapid, innovative, and agile technology solutions, Sierra Nevada Corporation (SNC) is currently developing a new space transportation system called the Dream Chaser.

The ultimate aim is to construct a multi-mission-capable space utility vehicle, while accelerating the overall development process for this critical capability...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Projektarbeit in der Industrie effizient gestalten

30.04.2015 | Veranstaltungen

Wie nehmen Pflanzen ihre Umwelt wahr?

30.04.2015 | Veranstaltungen

BMBF-Fachtagung „Arbeit in der digitalisierten Welt“: Die Anmeldefrist endet am 6. Mai 2015

30.04.2015 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Signal zur Einleitung der Schädlingsabwehr ist in Pflanzen doppelt gesichert

30.04.2015 | Biowissenschaften Chemie

Erfolgreich erprobt: Bremer Fernerkundungssensor visualisiert Methanemissionen von Ölfeldern

30.04.2015 | Energie und Elektrotechnik

Dorma und Kaba planen Zusammenschluss

30.04.2015 | Unternehmensmeldung